Lancet. 1986 Feb 22;1(8478):397-402.
In an unblinded trial of intravenous streptokinase (SK) in early acute myocardial infarction, 11 806 patients in one hundred and seventy-six coronary care units were enrolled over 17 months. Patients admitted within 12 h after the onset of symptoms and with no contraindications to SK were randomised to receive SK in addition to usual treatment and complete data were obtained in 11 712. At 21 days overall hospital mortality was 10.7% in SK recipients versus 13% in controls, an 18% reduction (p = 0.0002, relative risk 0.81). The extent of the beneficial effect appears to be a function of time from onset of pain to SK infusion (relative risks 0.74, 0.80, 0.87, and 1.19 for the 0-3, 3-6, 6-9, and 9-12 h subgroups). SK seems to be a safe drug for routine administration in acute myocardial infarction.
在一项关于静脉注射链激酶（SK）治疗早期急性心肌梗死的非盲法试验中，176个冠心病监护病房的11806例患者在17个月内入组。症状发作后12小时内入院且无SK禁忌证的患者被随机分配接受SK加常规治疗，11712例患者获得完整数据。21天时，SK接受者的总体医院死亡率为10.7%，而对照组为13%，降低了18%（p = 0.0002，相对风险0.81）。有益效果的程度似乎是从疼痛发作到SK输注时间的函数（0 - 3、3 - 6、6 - 9和9 - 12小时亚组的相对风险分别为0.74、0.80、0.87和1.19）。SK似乎是急性心肌梗死常规给药的安全药物。
